and FGF21 may need to cooperate with other PPARα-regulated genes to exert hepatic lowering effects; 2. While the rFGF21 dose (0.25mg/kg) was sufficient to exert actions in the Pparα+/+ mice (where endogenous FGF21 is also produced), it may not be sufficient for Pparα−/− mice (where no or little endogenous FGF21 is produced); 3. The rFGF21 may be lowering non-hepatic secretion of TG into the serum e.g. adipose tissue lipolysis, thereby lowering hypertriglyceridemia but not hepatic TGF levels.
